[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521764":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":35,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"BioMérieux","INDUSTRY",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Jean-François LLITJOS","CONTACT","+33761568397","jeanfrancois.llitjos@biomerieux.com",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Marie-Angelique CAZALIS","+33626807839","marie-angelique.cazalis@biomerieux.com",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Hopital Edouard Herriot","RECRUITING","Lyon","69003","France","FR",{"type":27,"coordinates":28},"Point",[29,30],4.84789,45.74906,{"lat":30,"lon":29},[33],{"name":34,"role":11,"phone":7,"phoneExt":7,"email":7},"Anne-Claire Lukaszewicz, PU-PH",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100521764","lung-infection-in-icu-lung-i3-100521764",false,"NCT06073834","LUNG INFECTION in ICU (LUNG-I3)","LUNG INFECTION in ICU","LUNG-I3","Inclusion Criteria:\n\nAll the following criteria\n\n* Age 18 years or greater\n* Severe ICU patients hospitalized for one of the above diseases:\n\n  * Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol\u002FL (\\>18 mg\u002FdL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20)\n  * Severe trauma (level I and II), Injury Severity Score ≥ 25 OR\n  * Burn with TBSA over 20%\n* NAD \\> 0.1 µg\u002Fkg\u002Fmin\n* At least 2 SOFA criteria ≥ 2 points\n\nExclusion Criteria:\n\n* Aspiration pneumonia\n* Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)\n* COPD\n* Smoke inhalation in burn patients\n* Participation in an intervention study\n* Pregnant or breastfeeding women\n* Immunocompromised patients, defined as\n\n  * patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease\n  * hematologic malignancies\n  * solid organ transplantation\n  * HIV infection with or without AIDS\n  * treatment with corticosteroids (\\> 3 months at any dosage or ≥ 1 mg\u002Fkg prednisone equivalent per day for \\> 7 day)\n  * treatment with other immunosuppressive drugs.","ALL","18 Years",{"count":48,"type":49},68,"ESTIMATED","OBSERVATIONAL","objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils",[53],"VAP - Ventilator Associated Pneumonia",[53,55,56,57,58],"Sepsis","Lung Infection","Broncho-alveolar Lavage","ICU","2025-02-10",{"date":61,"type":62},"2025-02-12","ACTUAL",{"date":64,"type":62},"2023-12-05",{"date":66,"type":49},"2027-06",{"name":5,"class":6},1]